Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLpro protease inhibitor
- Development stage
- Preclinical
- Lead developer
- Sunshine Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PLpro protease inhibitor is a small molecule drug candidate developed by Sunshine Biopharma under an exclusive worldwide royalty-bearing license agreement with the University of Arizona. It is designed to target SARS Coronavirus infections, including SARS-CoV-2, SARS-CoV, and MERS-CoV, by inhibiting the PLpro protease enzyme. The drug candidate is currently in preclinical development and has demonstrated efficacy in mouse models.
02
Targets
PLpro (Papain-like protease)
Beyond the preview
Go deeper on PLpro protease inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLpro protease inhibitor.